Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Lanqi Cen"'
Autor:
Lanqi Cen, Zhe Zhang, Yi Sun, Nandie Wu, Jie Shao, Zhaoye Qian, Manman Tian, Yaohua Ke, Baorui Liu
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background The clinical application of peptide vaccines in tumor immunotherapy holds significant promise. Peptide-based tumor vaccines are currently subject to certain limitations in clinical trials, including the challenge of inducing a sus
Externí odkaz:
https://doaj.org/article/d2986432684d451ebc6de3bd09004145
Autor:
Chunhua Li, Dan Lei, Yudong Huang, Yuanhao Jing, Wanru Wang, Lanqi Cen, Zijian Wei, Anni Chen, Xiaoyu Feng, Yushu Wang, Lixia Yu, Ying Chen, Rutian Li
Publikováno v:
Materials Today Bio, Vol 29, Iss , Pp 101281- (2024)
Ginsenoside Rh2 (G-Rh2) is a vital bioactive compound in Traditional Chinese Medicine, celebrated for its strong pharmacological properties, particularly its potent antitumor effects. However, its poor water solubility and limited bioavailability hav
Externí odkaz:
https://doaj.org/article/623d061afced4bc399c3e51320b09b5d
Autor:
Yaohua Ke, Kai Xin, Yaping Tao, Lin Li, Aoxing Chen, Jingyi Shao, Junmeng Zhu, Dinghu Zhang, Lanqi Cen, Yanhong Chu, Lixia Yu, Baorui Liu, Qin Liu
Publikováno v:
Advanced Science, Vol 11, Iss 14, Pp n/a-n/a (2024)
Abstract Tumor‐specific frameshift mutations encoding peptides (FSPs) are highly immunogenic neoantigens for personalized cancer immunotherapy, while their clinical efficacy is limited by immunosuppressive tumor microenvironment (TME) and self‐to
Externí odkaz:
https://doaj.org/article/01ba9fee29644d7199d05fd04b4c1bd2
Autor:
Qin Liu, Yanhong Chu, Jie Shao, Hanqing Qian, Ju Yang, Huizi Sha, Lanqi Cen, Manman Tian, Qiuping Xu, Fangjun Chen, Yang Yang, Weifeng Wang, Kai Wang, Lixia Yu, Jia Wei, Baorui Liu
Publikováno v:
Advanced Science, Vol 10, Iss 1, Pp n/a-n/a (2023)
Abstract Personalized neoantigen vaccines have shown strong immunogenicity in clinical trial, but still face various challenges in facilitating an efficient antitumor immune response. Here, a personalized neoantigen nanovaccine (PNVAC) platform for a
Externí odkaz:
https://doaj.org/article/421aa49d2acf4662a537301fb763cc00
Publikováno v:
Journal of Biomedical Research; Jul2024, Vol. 38 Issue 4, p369-381, 13p
Autor:
Huizi Sha, Qin Liu, Li Xie, Jie Shao, Lixia Yu, Lanqi Cen, Lin Li, Fangcen Liu, Hanqing Qian, Jia Wei, Baorui Liu
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Some of the mutant peptides produced by gene mutation transcription and translation have the ability to induce specific T cells, which are called new antigens. Neoantigen-based peptide, DNA, RNA, and dendritic cell vaccines have been used in the clin
Externí odkaz:
https://doaj.org/article/4ef8eaf20d1048ad8eea8167cee600a9
Autor:
Jie Shao, Qin Liu, Jie Shen, Xiaoping Qian, Jing Yan, Yahui Zhu, Xin Qiu, Changchang Lu, Lanqi Cen, Manman Tian, Juan Du, Baorui Liu
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Personal neoantigen vaccines are considered to be effective methods for inducing, amplifying and diversifying antitumor T cell responses. We recently conducted a clinical study that combined neoantigen nanovaccine with anti-PD-1 antibody. Here, we re
Externí odkaz:
https://doaj.org/article/fa8f4c58b4b043109140316ead1206b6
Autor:
Hengheng Dai, Ying Huang, Jingyi Guo, Lin Li, Yaohua Ke, Lanqi Cen, Fanyan Meng, Xinjie Chen, Baorui Liu, Xiaoping Qian
Publikováno v:
ACS Applied Materials & Interfaces. 14:52634-52642
Neoantigen vaccines have opened a new paradigm for cancer immunotherapy. Here, we constructed a neoantigen nanovaccine-HemoMap, with the ability to target lymph nodes and activate immune cells. We propose a HemoMap nanovaccine consisting of the mouse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::999c2d0ae8eb1bc2e775bfb092f8e03f
https://doi.org/10.1021/acsami.2c14379
https://doi.org/10.1021/acsami.2c14379
Autor:
Xinjie Chen, Lanqi Cen, Qin Liu, Yanhong Chu, Xiaoyu Feng, Yaohua Ke, Zhe Zhang, Hengheng Dai, Shuling Huang, Baorui Liu, Xiaoping Qian
Publikováno v:
Biomaterials Science. 10:6740-6748
Neoantigen-based tumor vaccines have been applied in patient-specific melanoma-derived immunogenic mutated epitopes (neoantigens), with potential antineoplastic and immunomodulating effects. Yet, their use is limited by different physicochemical prop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc0c85b1bba1c90dbb44b731f0f87d15
https://doi.org/10.1039/d2bm01340a
https://doi.org/10.1039/d2bm01340a
Autor:
Hanqing Qian, Manman Tian, Baorui Liu, Lixia Yu, Fangjun Chen, Huizi Sha, Jie Shao, Yanhong Chu, Ju Yang, lanqi Cen, Kai Wang, Qin Liu, Yang Yang, Weifeng Wang, Qiuping Xu, Jia Wei
Publikováno v:
Advanced science (Weinheim, Baden-Wurttemberg, Germany).
Personalized neoantigen vaccines have shown strong immunogenicity in clinical trial, but still face various challenges in facilitating an efficient antitumour immune response. Here we prepared a personalized neoantigen nanovaccine (PNVAC) platform fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c763b9f4d5f45d3c141d0fb64413a779
https://pubmed.ncbi.nlm.nih.gov/36351249
https://pubmed.ncbi.nlm.nih.gov/36351249